脂质体两性霉素B (AmBisome)在地中海内脏利什曼病:一项多中心试验。

Quarterly Journal of Medicine Pub Date : 1994-02-01

R N Davidson, L Di Martino, L Gradoni, R Giacchino, R Russo, G B Gaeta, R Pempinello, S Scott, F Raimondi, A Cascio

{"title":"脂质体两性霉素B (AmBisome)在地中海内脏利什曼病:一项多中心试验。","authors":"R N Davidson, L Di Martino, L Gradoni, R Giacchino, R Russo, G B Gaeta, R Pempinello, S Scott, F Raimondi, A Cascio","doi":"","DOIUrl":null,"url":null,"abstract":"Thirty-one patients with visceral leishmaniasis (VL) caused by Leishmania infantum received liposomal amphotericin B (AmBisome) in a multi-centre study. Ten immunocompetent patients (six children) received 1-1.38 mg/kg/day for 21 days, and ten (nine children) received 3 mg/kg/day for 10 days. All were cured without significant adverse events and without relapse during 12-24 months of follow-up. Eleven immunocompromised adults, including seven co-infected with HIV (four with AIDS) received 100 mg (1.38-1.85 mg/kg) daily for 21 days. All were initially considered cured, but eight relapsed clinically and parasitologically at 3-22 months. Liposomal amphotericin B is a new, safe and effective drug for the treatment of VL.","PeriodicalId":54520,"journal":{"name":"Quarterly Journal of Medicine","volume":"87 2","pages":"75-81"},"PeriodicalIF":0.0000,"publicationDate":"1994-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.\",\"authors\":\"R N Davidson, L Di Martino, L Gradoni, R Giacchino, R Russo, G B Gaeta, R Pempinello, S Scott, F Raimondi, A Cascio\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Thirty-one patients with visceral leishmaniasis (VL) caused by Leishmania infantum received liposomal amphotericin B (AmBisome) in a multi-centre study. Ten immunocompetent patients (six children) received 1-1.38 mg/kg/day for 21 days, and ten (nine children) received 3 mg/kg/day for 10 days. All were cured without significant adverse events and without relapse during 12-24 months of follow-up. Eleven immunocompromised adults, including seven co-infected with HIV (four with AIDS) received 100 mg (1.38-1.85 mg/kg) daily for 21 days. All were initially considered cured, but eight relapsed clinically and parasitologically at 3-22 months. Liposomal amphotericin B is a new, safe and effective drug for the treatment of VL.\",\"PeriodicalId\":54520,\"journal\":{\"name\":\"Quarterly Journal of Medicine\",\"volume\":\"87 2\",\"pages\":\"75-81\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1994-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Quarterly Journal of Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Quarterly Journal of Medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

在一项多中心研究中，31例由婴儿利什曼原虫引起的内脏利什曼病(VL)患者接受了两性霉素B脂质体治疗。10例免疫功能正常的患者(6例儿童)接受1 ~ 1.38 mg/kg/天治疗，连续21天;10例(9例儿童)接受3mg /kg/天治疗，连续10天。随访12-24个月，全部治愈，无明显不良反应，无复发。11名免疫功能低下的成年人，包括7名合并感染艾滋病毒(4名合并艾滋病)，每天服用100毫克(1.38-1.85毫克/公斤)，持续21天。所有患者最初都被认为治愈，但其中8人在3-22个月时临床和寄生虫学复发。两性霉素B脂质体是一种安全有效的治疗VL的新药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.

Thirty-one patients with visceral leishmaniasis (VL) caused by Leishmania infantum received liposomal amphotericin B (AmBisome) in a multi-centre study. Ten immunocompetent patients (six children) received 1-1.38 mg/kg/day for 21 days, and ten (nine children) received 3 mg/kg/day for 10 days. All were cured without significant adverse events and without relapse during 12-24 months of follow-up. Eleven immunocompromised adults, including seven co-infected with HIV (four with AIDS) received 100 mg (1.38-1.85 mg/kg) daily for 21 days. All were initially considered cured, but eight relapsed clinically and parasitologically at 3-22 months. Liposomal amphotericin B is a new, safe and effective drug for the treatment of VL.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Quarterly Journal of Medicine

自引率

0.00%

发文量

期刊最新文献

Analysis of RNA translation with a deep learning architecture provides new insight into translation control. Aortic dissection. Spontaneous periodic hypothermia Unexplained cyanosis caused by hepatopulmonary syndrome in a girl with APECED syndrome. Predicting operative mortality after coronary artery bypass surgery in males.